


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (previously presented): A compound of formula (I)



wherein ring A represents a benzene ring which may have a substituent(s) wherein the substituent(s) is 1 to 5 of optional substituent(s) selected from the group consisting of methyl, ethyl, a fluorine atom, a chlorine atom, methoxy, ethoxy, difluoromethoxy, hydroxy, acetyl, trifluoromethoxy, methylsulfonyl, acetylamino, methylsulfonylamino, 1-hydroxy-1-methylethyl, 1-propenyl, and cyano;

ring B represents a benzene ring which may have a substituent(s), a thiophene ring which may have a substituent(s) an indan ring which may have a substituent(s), a 1,3-benzodioxole ring which may have a substituent(s), a cyclopentane ring which may have a substituent(s), a cyclohexane ring which may have a substituent(s), or a cycloheptane ring which may have a substituent(s), wherein the substituent(s) is 1 to 5 of optional substituent(s) selected from the group consisting of methyl, ethyl propyl, a fluorine atom, a chlorine atom, methoxy, and ethoxy;

K represents C1-4 alkylene which may be substituted with 1 to 5 of optional substituent(s) selected from the group consisting of methyl, a fluorine atom, hydroxy, and oxo;

Q represents methylene, ethylene, -O-, or -CH₂-O-;

M represents a bond, C1-4 alkylene which may have a substituent(s), or C2-4 alkenylene which may have a substituent(s), wherein the substituent(s) is 1 to 5 of optional substituent(s) selected from the group consisting of methyl and hydroxy;

ring D represents a benzene ring which may have a substituent(s), a pyrrole ring which may have a substituent(s), an imidazole ring which may have a substituent(s), a pyrazole ring which may have a substituent(s), an oxazole ring which may have a substituent(s), a thiazole ring which may have a substituent(s), or a thiophene ring which may have a substituent(s), wherein the substituent(s) is 1 to 5 of optional substituent(s) selected from the group consisting of carboxy, methyl, a fluorine atom, a chlorine atom, methoxycarbonyl, ethoxycarbonyl, aminocarbonyl N-methylaminocarbonyl, N,N-dimethylaminocarbonyl, and acetyl;

ring E represents a benzene ring which may have a substituent(s), wherein the substituent(s) is 1 to 5 of optional substituent(s) selected from the group consisting of methyl, a chlorine atom, a fluorine atom, methoxy, and ethoxy;


L represents a bond, -CH₂-, -O-, -S-, -SO-, -SO₂- or -NH-;


Z represents -COOH; -CONHSO₂R¹, in which R¹ represents C1-8 alkyl which may be substituted, a benzene ring which may have a substituent(s), or a pyridine ring which may have a substituent(s), a thiophene ring which may have a substituent(s), a furan ring which may have a substituent(s), an imidazole ring which may have a substituent(s), a thiazole ring which may have a substituent(s), an isoxazole ring which may have a substituent(s), a morpholine ring which may have a substituent(s), wherein the substituent(s) is 1 to 5 of optional substituent(s) selected from the group consisting of methyl, tert-butyl, a chlorine atom, a fluorine atom, trifluoromethyl, methoxy, trifluoromethoxy, and acetyl; and

t represents 0 or 1, or

a salt thereof, or a solvate thereof .

2. (Original): The compound according to claim 1, wherein the compound of formula (I) is an optically active compound of formula (I-A):



wherein  represents β -configuration; and other symbols have the same meanings as described in claim 1.

3.-4. (canceled).


5. (Original): The compound according to claim 1, wherein ring B is an indane ring which may have a substituent(s).

6. (previously presented): The compound according to claim 1, wherein Q is methylene or ethylene .

7. (Original) The compound according to claim 1, wherein ring D is a benzene ring which may have a substituent(s), a pyrazole ring which may have a substituent(s) or a pyrrole ring which may have a substituent(s).


8. (canceled).

9. (Original) The compound according to claim 1, wherein



is methylene which may be substituted, ethylene which may be substituted, propylene which may be substituted, or ethenylene which may be substituted.

10. (previously presented): The compound according to claim 1,
wherein ring A is a benzene ring which may have a substituent(s);
ring B is an indane ring which may have a substituent(s);
ring D is a benzene ring which may have a substituent(s), a pyrazole ring which may have a substituent(s) or a pyrrole ring which may have a substituent(s);



is methylene which may be substituted, ethylene which may be substituted, propylene which may be substituted, or ethenylene which may be substituted; and

Z is -COOH; -CONHSO₂R¹, in which R¹ C1-8 alkyl which may be substituted, a benzene ring which may have a substituent(s).

11. (Original) The compound according to claim 1, which is selected from the group consisting of:

- (1) {1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxypropyl]-1H-pyrrol-3-yl}acetic acid,
- (2) (1-{(2S)-2-[(S)-(3,5-dimethoxy-4-methylphenyl)(hydroxy)methyl]-5-thien-3-ylpentyl}-1H-pyrrol-3-yl)acetic acid,
- (3) {1-[(2S,3S)-2-(1,3-benzodioxol-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxypropyl]-1H-pyrrol-3-yl}acetic acid,
- (4) {1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-hydroxy-3-(3,4,5-trimethoxyphenyl)propyl]-1H-pyrrol-3-yl}acetic acid,
- (5) {1-[(2S,3S)-3-(4-acetyl-3,5-dimethoxyphenyl)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-hydroxypropyl]-1H-pyrrol-3-yl}acetic acid,
- (6) {1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(4-ethyl-3,5-dimethoxyphenyl)-3-hydroxypropyl]-1H-pyrrol-3-yl}acetic acid,
- (7) 3-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxypropyl]-1H-pyrrol-3-yl}propanoic acid,
- (8) 3-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-hydroxy-3-(3,4,5-trimethoxyphenyl)propyl]-1H-pyrrol-3-yl}propanoic acid,
- (9) 3-{1-[(2S,3S)-3-(4-acetyl-3,5-dimethoxyphenyl)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-hydroxypropyl]-1H-pyrrol-3-yl}propanoic acid,

- (10) 3-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(4-ethyl-3,5-dimethoxyphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}propanoic acid,
- (11) 2-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}-N-(methylsulfonyl)acetamide,
- (12) [1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxylpropyl]-4-(methoxycarbonyl)-1H-pyrrol-3-yl]acetic acid,
- (13) N-(3-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}propanoyl)-2-methylbenzenesulfonamide,
- (14) (2E)-3-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}acrylic acid,
- (15) 2-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}-2-methylpropanoic acid, and
- (16) (2E)-3-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}-2-methylacrylic acid.

12. (previously presented): A pharmaceutical composition comprising the compound of formula (I) according to claim 1, a salt thereof, or a solvate thereof, and a pharmaceutically acceptable diluent or carrier.

13. (previously presented): The pharmaceutical composition according to claim 12, which is an LPA receptor antagonist, wherein the LPA receptor is an EDG-2 receptor.

14. (canceled).

15. (previously presented): The pharmaceutical composition according to claim 12, which is an agent for treatment of urinary system disease.

16. (currently amended): A method for treatment of urinary system disease selected from the group consisting of prostatic hypertrophy, neurogenic bladder dysfunction disease, dysuria, pollakiuria, night urination and urodynia, which comprises administering to a mammal an effective amount of the compound of formula (I) according to claim 1, a salt thereof, or a solvate thereof.

17. (canceled).

18. (previously presented): A pharmaceutical composition comprising a combination of the compound of formula (I) according to claim 1, a salt thereof, or a solvate thereof with at least one agent selected from an LPA receptor antagonist, an $\alpha 1$ blocking agent, an anticholinergic agent, a 5α -reductase inhibitor and an anti-androgenic agent.